Trial Profile
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NICOLAS
- 11 Nov 2020 Results (n=74; at data cut-off Aug 2019) assessing primary efficacy analysis published in the Journal of Thoracic Oncology.
- 10 Aug 2020 Status changed from active, no longer recruiting to completed.
- 06 Aug 2020 This trial has been completed in Germany according to European Clinical Trials Database record.